

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	10/588,409
Filing Date	August 3, 2006
First Named Inventor	Tidmarsh, George
Art Unit	1624
Examiner Name	Unassigned
Attorney Docket Number	021305-004010US

[illegible][illegible]

Examiner Signature	/Bahar Schmidtman/	Date Considered	07/07/2011
-----------------------	--------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPPEP 901.04. ³ EPO Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			Complete if Known Application Number 10/588,409 Filing Date August 3, 2006 First Named Inventor Tidmarsh, George Art Unit 1624 Examiner Name Unassigned Attorney Docket Number 021305-004010US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				
Sheet	2	of	3	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AL	ARANEO et al., "Biweekly Low-Dose Sequential Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (GFP): A Highly Active Novel Therapy for Metastatic Adenocarcinoma of the Exocrine Pancreas," <u>Cancer Invest.</u> , 21(4):489-496 (2003).	<input type="checkbox"/>	
	AM	BRIASOULIS et al., "Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group," <u>J. Clin. Oncol.</u> , 18(20):3535-3544 (2000).	<input type="checkbox"/>	
	AN	BURRIS et al., "Assessing Clinical Benefit in the Treatment of Pancreas Cancer: Gemcitabine Compared to 5-Fluorouracil," <u>Eur. J. Cancer</u> , 33(Suppl 1):S18-S22 (1997).	<input type="checkbox"/>	
	AO	KOZUCH et al., "Irinotecan Combined with Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (G-FLIP) is an Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer," <u>The Oncologist</u> , 6:488-495 (2001).	<input type="checkbox"/>	
	AP	NICULESCU-DUVAZ, I., "Glufosfamide (Baxter Oncology)," <u>Curr. Opin. Investig. Drugs</u> , 3(10):1527-1532 (2002).	<input type="checkbox"/>	
	AQ	NOBLE et al., "Gemcitabine. A review of its Pharmacology and Clinical Potential in Non-Small Cell Lung Cancer and Pancreatic Cancer," <u>Drugs</u> , 54(3): 447-472 (1997).	<input type="checkbox"/>	
	AR	ROTHENBERG et al., "A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer," <u>Ann. Oncol.</u> , 7:347-353 (1996).	<input type="checkbox"/>	
	AS	STEPHENS, C. D., "Gemcitabine: A New Approach to Treating Pancreatic Cancer," <u>Oncol. Nurs. Forum</u> 25(1):87-93 (1998).	<input type="checkbox"/>	
	AT	ZISKE et al., "Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine," <u>Br. J. Cancer</u> , 89:1413-1417 (2003).	<input type="checkbox"/>	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Examiner Signature	/Bahar Schmidtman/	Date Considered	07/07/2011
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/588,409
				Filing Date	August 3, 2006
				First Named Inventor	Tidmarsh, George
				Art Unit	1624
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	021305-004010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AU	"Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint", News Release, Threshold Pharmaceuticals Inc., February 27, 2007.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Examiner Signature	/Bahar Schmidtman/	Date Considered	07/07/2011
-----------------------	--------------------	--------------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.